The first part of this series (Pharmacy Today, September 2017) reviewed seven new FDA-approved therapeutic agents marketed in 2017, and the second part (Pharmacy Today, December 2017) reviewed nine agents. This third part of the series covers nine additional therapeutic agents marketed in 2017: delafloxacin meglumine, meropenem trihydrate/vaborbactam, secnidazole, benznidazole, letermovir, naldemedine tosylate, abaloparatide, etecalcetide hydrochloride, and latanoprostene bunod. The authors review indications, mechanisms of action, and information on dosage and administration for these new agents, as well as their most important pharmacokinetic properties, adverse events, and other risks and precautions. They compare the new agents with older drugs marketed for the same indications and identify the advantages and disadvantages of the new drugs.
At the completion of this activity, the pharmacist will be able to:
- Identify the new therapeutic agents and explain their appropriate use.
- Identify the indications and mechanisms of action of the new agents.
- Identify the most important adverse events and other risks of the new agents.
- State the route of administration for each new drug and the most important considerations for dosage and administration.
- Compare the new agents with older medications to which they are most similar in properties and/or use and identify the most important advantages and disadvantages of the new drugs.
Activity type: Knowledge-based
Target Audience: Pharmacists and Pharmacy Technicians
Learning level: 1
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-18-134-H01-P.
To obtain credit for "New Therapeutic Agents Marketed in 2017: Part 3," complete the assessment with a grade of 70% or better, complete the evaluation, and then claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted. The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: March 1, 2018
Expiration date: March 1, 2021 - NO CREDIT GRANTED AFTER THIS DATE
"New Therapeutic Agents Marketed in 2017: Part 3” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.
Daniel A. Hussar, Ph.D, Remington Professor of Pharmacy, Philadelphia College of Pharmacy at the University of the Sciences, Philadelphia, PA
Eric F. Hussar, M.D., Primary Care Physician, Susquehanna Family Medicine, Marietta, PA
Mark Johnson, PharmD, BCPS, Professor and Vice Chair of Pharmacy Practice, Director of Postgraduate Education, Shenandoah University Bernard J. Dunn School of Pharmacy, Winchester, VA
Daniel A. Hussar, Ph.D; Eric F. Hussar, M.D.; Mark Johnson, PharmD, BCPS; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
Computer and internet access are required to complete this activity. Please visit our website and view the Technology System Requirements to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-18-134-H01-P||0.2 CEUs||March 01, 2018 - March 01, 2021|
|ACPE# 0202-0000-18-134-H01-T||0.2 CEUs||March 01, 2018 - March 01, 2021|